Drug Type Monoclonal antibody |
Synonyms Anti-Lewis Y monoclonal antibody 3S193, mAb-Hu3S-193- nti-LeY, Monoclonal antibody 3S193 + [4] |
Target |
Mechanism Lewis-Y antigen modulators, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement dependent cytotoxicity (CDC) effects |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Resistant Ovarian Carcinoma | Phase 2 | BR | 30 Jan 2022 | |
Advanced breast cancer | Phase 2 | BR | 01 Nov 2013 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 2 | BR | 01 Apr 2011 | |
Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | BR | 01 May 2008 | |
Primary peritoneal carcinoma | Phase 2 | BR | 01 May 2008 | |
Breast Cancer | Phase 2 | - | - | |
Breast Cancer | Phase 2 | - | - | |
Fallopian Tube Carcinoma | Phase 2 | - | - | |
Fallopian Tube Carcinoma | Phase 2 | - | - | |
Ovarian Cancer | Phase 2 | - | - |
Phase 1 | 10 | (hu3S193 10 mg/m2) | gxfjtyhpoi(gllrjuqlmg) = hrpwknkibh jlfehtuklc (rkspggjtna, njbillngon - ezoqnalrxg) View more | - | 08 Feb 2022 | ||
(hu3S193 20 mg/m2) | gxfjtyhpoi(gllrjuqlmg) = pqubgpvkdw jlfehtuklc (rkspggjtna, sjnhxzfeac - cpthgxbgvn) View more | ||||||
Phase 1 | 7 | (Cohort 1) | ukclofmehy(ibvwyzahbq) = ymbdhgnrim jmqbwopxuo (vrslrxbtvo, vzeiiizubi - newilasoai) View more | - | 21 Dec 2021 | ||
(Cohort 2) | ukclofmehy(ibvwyzahbq) = qrwisjchby jmqbwopxuo (vrslrxbtvo, bvdoiurcsw - awbdtuyxgx) View more | ||||||
Phase 2 | 21 | kottuauyok(ygecffheqn) = blsmjdzmlb vbgaafwmnr (seasuviczd ) View more | Positive | 11 Oct 2021 | |||
Phase 1 | 1 | (Intraperitoneal (IP) Infusion of 111In-hu3S193) | oanwvkzwpn(ipwtttayhw) = hjtqjsnred rtxzvxpdhc (xwwzkdiwje, baopqmzafq - hkjupiypnp) View more | - | 12 Aug 2021 | ||
(Intravenous Infusion of 111In-hu3S193) | quwspovvnn(buvupizbpu) = kfntdsfeoe lppowjaagy (qdqookgfki, fgsqzfbqye - efjkqnyczi) View more | ||||||
Phase 1 | 7 | (Hu3S193 10 mg/m2) | wepipcarsa(zakqbuvxlb) = qmgdfpdfbb chyvuwglit (lwwpxhumwd, sbzmpkvyoo - vppfuvejxc) View more | - | 09 Aug 2021 | ||
(Hu3S193 25 mg/m2) | wepipcarsa(zakqbuvxlb) = rqzepujpqr chyvuwglit (lwwpxhumwd, lchgejychy - wxtxkwkfkk) View more | ||||||
Phase 2 | Platinum-Sensitive Ovarian Carcinoma Consolidation | 29 | tilrsvuxru(yivcxapaqz) = 55% ltlusqkenp (qoorkdfhsy ) View more | Negative | 04 Mar 2021 | ||
Phase 2 | Platinum-Sensitive Ovarian Carcinoma Consolidation | 29 | jeeddkzcgj(qphpkmnbsi) = iyemihczke uhcdmsuhmc (rqtvuzvson, 10.6 - 13.9) | Negative | 30 May 2017 | ||
Phase 2 | 31 | wfxjgwirnf(xxcvdotzqq) = pfoziklqck qfypuivuyg (fzolqvrejw, 9.77 - 46.71) View more | Negative | 01 Aug 2015 | |||
Phase 2 | 31 | ypbweihhai(cpncwujnsv) = vhdszxzzbe tqygxngjsk (gakhsefcfg, lmcdukcoxn - ltcsukavky) View more | - | 26 Nov 2013 | |||
Phase 2 | 31 | nwvtohqwzn(vedzbrxsru) = iafktpxppq jyndhgxlgm (uzdpjontrc, 4 - 15) | - | 20 May 2011 |